Precigen Inc (PGEN) Stock Price, Quote & News

Company Profile

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell t...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 556 9900

Website: precigen.com

Address:

20374 Seneca Meadows Parkway, Germantown, United States

M22 Jul. 4 at 2:18 AM

$PGEN I’m lease my fellow shareholders pray for me and my wife A storm came through tonight and destroyed our home

3 · Reply

M22 Jul. 3 at 7:20 PM

$PGEN. I don’t know if this was posted before - https://youtube.com/watch?v=vxGb57zWfgs&is=U3kDYovk5zcvRSqS

0 · Reply

M22 Jul. 3 at 6:23 PM

$PGEN kind of long with lots of information most share holders already know, but skip ahead and there’s good info. Worth listening to - https://youtube.com/watch?v=09of9Q26IKE&is=Hw_KBoG0PA4fOzzu

0 · Reply

Tapa Jul. 3 at 6:07 PM

$PGEN Happy independence day.

0 · Reply

chungana Jul. 3 at 8:03 AM

$PGEN Whoa!$ XBI blew away the crooks!$ Tremendously stupendously bullish for biotechs and PGEN, in particulat!$ 🥳🤩🤗😍

0 · Reply

forgottenchuck Jul. 3 at 2:40 AM

$PGEN wow what a close today

0 · Reply

Jason_Craps Jul. 2 at 8:04 PM

$PGEN Very nice close today. Wishing a GREAT Fourth to all!

0 · Reply

forgottenchuck Jul. 2 at 7:46 PM

$PGEN looks like the weaker hands are washed out

0 · Reply

M22 Jul. 2 at 4:21 PM

$PGEN I just got my monthly cash back from my Fidelity credit card and bought a little more. It’s not much but 33 shares at $5.38 is 33 more shares that I didn’t have yesterday. Now waiting for my $GPIQ dividends. That’s when I pick up a couple of hundred more shares. No worries LFG 👍💎🤲🏻

1 · Reply

Tapa Jul. 2 at 2:56 PM

$PGEN don't give in to the CROOKS.

1 · Reply

Precigen Transcript: AGM 2026

Jun 15, 2026, 6:40 AM EDT - 19 days ago

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Jun 11, 2026, 8:00 AM EDT - 23 days ago

Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices

Jun 8, 2026, 9:20 AM EDT - 26 days ago

Precigen Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

2026-05-31T21:35:05.000Z - 4 weeks ago

Precigen presents long-term follow-up data from study of Papzimeos

May 30, 2026, 2:30 PM EDT - 5 weeks ago

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

2026-05-28T10:13:45.000Z - 5 weeks ago

Precigen price target raised to $14 from $11 at H.C. Wainwright

2026-05-27T11:17:06.000Z - 5 weeks ago

Precigen receives orphan drug exclusivity for papzimeos in the U.S.

May 27, 2026, 7:00 AM EDT - 5 weeks ago

Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States

May 26, 2026, 8:05 AM EDT - 5 weeks ago

Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference

2026-05-14T10:22:58.000Z - 7 weeks ago

Precigen price target raised to $11 from $10 at H.C. Wainwright

2026-05-14T09:56:27.000Z - 7 weeks ago

Precigen price target raised to $11 from $9 at Citizens

2026-05-13T21:07:28.000Z - 7 weeks ago

Precigen reports Q1 EPS (2c) vs. (18c) last year

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Precigen Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Precigen Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 7 weeks ago

Precigen Quarterly report: Q1 2026

May 13, 2026, 4:05 PM EDT - 7 weeks ago

Precigen Reports First Quarter 2026 Financial Results and Business Updates

May 7, 2026, 4:05 PM EDT - 2 months ago

Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Precigen Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Precigen Proxy statement: Proxy filing

2026-04-07T12:02:54.000Z - 3 months ago

Precigen sees Q1 revenue exceeding $18M, consensus $20.8M

2026-04-07T11:17:44.000Z - 3 months ago

Precigen sees ‘robust uptake’ in usage of Papzimeos since its launch

Apr 7, 2026, 7:00 AM EDT - 3 months ago

Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million

Mar 31, 2026, 11:00 AM EDT - 3 months ago

Precigen Transcript: Fireside chat

Mar 30, 2026, 8:30 AM EDT - 3 months ago

Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31

2026-03-26T15:25:13.000Z - 3 months ago

Precigen jumps on Q1 outlook despite earnings miss

2026-03-26T10:10:56.000Z - 3 months ago

Precigen price target raised to $10 from $9 at H.C. Wainwright

2026-03-26T10:00:46.000Z - 3 months ago

Precigen price target raised to $9 from $8 at Citizens

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Precigen Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Precigen Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 3 months ago

Precigen Earnings release: Q4 2025

Mar 25, 2026, 4:05 PM EDT - 3 months ago

Precigen Reports Full Year 2025 Financial Results and Business Updates

Mar 11, 2026, 4:05 PM EDT - 4 months ago

Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25

Jan 20, 2026, 8:05 AM EST - 5 months ago

New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis

Jan 15, 2026, 10:30 AM EST - 6 months ago

Precigen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 10:30 AM EST - 6 months ago

Precigen Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 6 months ago

Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 4:05 PM EST - 6 months ago

Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-03T15:00:13.000Z - 7 months ago

JPMorgan healthcare analysts hold an analyst/industry conference call

2025-11-14T11:16:04.000Z - 8 months ago

Precigen price target raised to $9 from $8.50 at H.C. Wainwright

2025-11-13T21:31:56.000Z - 8 months ago

Precigen reports Q3 EPS ($1.06) vs. (9c) last year

Nov 13, 2025, 4:30 PM EST - 8 months ago

Precigen Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Precigen Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Precigen Earnings release: Q3 2025

Nov 13, 2025, 4:05 PM EST - 8 months ago

Precigen Reports Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 4:30 PM EST - 8 months ago

Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13

2025-10-13T11:05:34.000Z - 9 months ago

Precigen presents long-term data demonstrating durable responses to PAPZIMEOS

Oct 13, 2025, 7:00 AM EDT - 9 months ago

Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis

Sep 3, 2025, 7:00 AM EDT - 10 months ago

Precigen Announces Up to $125 Million Non-Dilutive Financing

Sep 2, 2025, 11:00 AM EDT - 10 months ago

Precigen Transcript: Fireside Chat

Aug 25, 2025, 8:05 AM EDT - 11 months ago

Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright

2025-08-19T21:35:16.000Z - 11 months ago

Precigen files to sell 143.81M shares of common stock for holders

Aug 19, 2025, 8:00 AM EDT - 11 months ago

Precigen Registration statement: Registration Filing

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Precigen Transcript: Investor Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Precigen Press release: Investor Update

Aug 18, 2025, 8:00 AM EDT - 11 months ago

Precigen Slides: Investor Update

Aug 15, 2025, 7:18 AM EDT - 11 months ago

US FDA approves Precigen's immunotherapy for rare respiratory disease

Aug 15, 2025, 7:00 AM EDT - 11 months ago

Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Aug 12, 2025, 7:00 AM EDT - 11 months ago

Precigen Quarterly report: Q2 2025

May 16, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

May 16, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

May 14, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025, 4:00 PM EDT - 1 year ago

Precigen Quarterly report: Q1 2025

May 14, 2025, 4:00 PM EDT - 1 year ago

Precigen Earnings release: Q1 2025

May 6, 2025, 8:00 AM EDT - 1 year ago

Precigen Proxy statement: Proxy Filing

Apr 16, 2025, 8:05 AM EDT - 1 year ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Annual report: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

Precigen Earnings release: Q4 2024

Mar 19, 2025, 4:05 PM EDT - 1 year ago

Precigen Reports Full Year 2024 Financial Results and Business Updates

Mar 13, 2025, 8:05 AM EDT - 1 year ago

Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th

Feb 25, 2025, 8:05 AM EST - 1 year ago

FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025

Jan 16, 2025, 12:00 PM EST - 1 year ago

Precigen Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:00 AM EST - 1 year ago

Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:30 AM EST - 1 year ago

Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 7:00 AM EST - 1 year ago

Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis

Dec 27, 2024, 9:00 AM EST - 1 year ago

Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock

Nov 19, 2024, 10:55 AM EST - 1 year ago

Precigen Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 4:30 PM EST - 1 year ago

Precigen Reports Third Quarter 2024 Financial Results and Business Updates

Nov 14, 2024, 4:00 PM EST - 1 year ago

Precigen Quarterly report: Q3 2024

Nov 14, 2024, 4:00 PM EST - 1 year ago

Precigen Earnings release: Q3 2024

Nov 12, 2024, 4:05 PM EST - 1 year ago

Precigen to Participate in the Stifel 2024 Healthcare Conference

Sep 16, 2024, 4:30 PM EDT - 1 year ago

Precigen to Participate in the 2024 Cantor Global Healthcare Conference

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings release: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates

Aug 9, 2024, 8:00 AM EDT - 2 years ago

Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th

Aug 7, 2024, 9:30 PM EDT - 2 years ago

Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock

Aug 6, 2024, 4:04 PM EDT - 2 years ago

Precigen Announces Proposed $30 Million Public Offering of Common Stock

Aug 6, 2024, 4:01 PM EDT - 2 years ago

Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch

Jul 23, 2024, 8:01 AM EDT - 2 years ago

Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Transcript: Study Result

Jun 3, 2024, 7:00 PM EDT - 2 years ago

Precigen Press release: Study Result

Jun 3, 2024, 9:30 AM EDT - 2 years ago

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response

May 28, 2024, 8:00 AM EDT - 2 years ago

Precigen Proxy statement: Proxy Filing

May 23, 2024, 5:00 PM EDT - 2 years ago

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting

May 14, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports First Quarter 2024 Financial Results and Business Updates

May 14, 2024, 4:00 PM EDT - 2 years ago

Precigen Quarterly report: Q1 2024

May 14, 2024, 4:00 PM EDT - 2 years ago

Precigen Earnings release: Q1 2024

May 8, 2024, 4:05 PM EDT - 2 years ago

Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting

Apr 24, 2024, 10:20 AM EDT - 2 years ago

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Apr 24, 2024, 9:00 AM EDT - 2 years ago

Actym Therapeutics Appoints Thomas Smart as CEO

ANAB XOMA

Mar 28, 2024, 4:05 PM EDT - 2 years ago

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings Call Transcript: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Annual report: Q4 2023

Mar 19, 2024, 4:30 PM EDT - 2 years ago

Precigen Earnings release: Q4 2023

Mar 19, 2024, 4:05 PM EDT - 2 years ago

Precigen Reports Full Year 2023 Financial Results and Business Updates

Mar 12, 2024, 4:05 PM EDT - 2 years ago

Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

Mar 5, 2024, 4:05 PM EST - 2 years ago

Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th

Feb 13, 2024, 3:20 PM EST - 2 years ago

Precigen Transcript: Oppenheimer 34th Annual Healthcare Life Sciences Conference (Virtual)

Feb 6, 2024, 4:05 PM EST - 2 years ago

Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

M22 Jul. 4 at 2:18 AM

$PGEN I’m lease my fellow shareholders pray for me and my wife A storm came through tonight and destroyed our home

3 · Reply

M22 Jul. 3 at 7:20 PM

$PGEN. I don’t know if this was posted before - https://youtube.com/watch?v=vxGb57zWfgs&is=U3kDYovk5zcvRSqS

0 · Reply

M22 Jul. 3 at 6:23 PM

$PGEN kind of long with lots of information most share holders already know, but skip ahead and there’s good info. Worth listening to - https://youtube.com/watch?v=09of9Q26IKE&is=Hw_KBoG0PA4fOzzu

0 · Reply

Tapa Jul. 3 at 6:07 PM

$PGEN Happy independence day.

0 · Reply

chungana Jul. 3 at 8:03 AM

$PGEN Whoa!$ XBI blew away the crooks!$ Tremendously stupendously bullish for biotechs and PGEN, in particulat!$ 🥳🤩🤗😍

0 · Reply

forgottenchuck Jul. 3 at 2:40 AM

$PGEN wow what a close today

0 · Reply

Jason_Craps Jul. 2 at 8:04 PM

$PGEN Very nice close today. Wishing a GREAT Fourth to all!

0 · Reply

forgottenchuck Jul. 2 at 7:46 PM

$PGEN looks like the weaker hands are washed out

0 · Reply

M22 Jul. 2 at 4:21 PM

1 · Reply

Tapa Jul. 2 at 2:56 PM

$PGEN don't give in to the CROOKS.

1 · Reply

RayD73 Jul. 2 at 1:00 PM

$PGEN It's surprising that we get such a negative reaction to insiders selling some of their stock. Like a lot of us long term investors they haven't had much opportunity to "take something off the table". It doesn't mean something is wrong, just prudence. Most of them literally have their entire financial life tied up in this stock. Look at what they own, not what they're selling!!!

0 · Reply

StockDad0927 Jul. 2 at 12:27 AM

$PGEN We didn’t even have news and we ran to $6. Should be very exciting to end the year.

0 · Reply

StockDad0927 Jul. 2 at 12:26 AM

$PGEN I’d call this a healthy dip, great chance to buy more. We know what we are sitting on.

0 · Reply

Wacousta Jul. 1 at 10:28 PM

$PGEN FYI https://investors.precigen.com/static-files/a176dd82-2a90-454c-a770-7c06ec4965c1

0 · Reply

Enjoyycall Jul. 1 at 9:11 PM

$PGEN This run up price $6 might prove to be interesting in the future. Just a random thought

0 · Reply

chungana Jul. 1 at 7:54 PM

$PGEN

0 · Reply

chungana Jul. 1 at 7:54 PM

$PGEN

0 · Reply

blue_horseshoe_9P Jul. 1 at 7:32 PM

$PGEN Freaking shorts always win. Such BS.

1 · Reply

forgottenchuck Jul. 1 at 6:23 PM

$PGEN

0 · Reply

forgottenchuck Jul. 1 at 6:12 PM

$PGEN if it dips below 5 im loading up bigtime

0 · Reply

Wacousta Jul. 1 at 4:34 PM

$PGEN FYI https://investors.precigen.com/node/15056/html

0 · Reply

RayD73 Jul. 1 at 2:57 PM

$PGEN Shorts working hard to take this down but they are running out of time. Buy every dip, this is going materially higher.

0 · Reply

Market Cap	2.01B
Revenue (ttm)	9.68M
Net Income (ttm)	-250.64M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,589.26%
Debt to Equity Ratio	4.62

Volume	4,766,100
Avg Vol	4,701,202
Day's Range	N/A - N/A
Shares Out	356.51M
Stochastic %K	65%
Beta	1.00
Analysts	Sell
Price Target	$12.50